This is most likely achieved by the downregulation of TNF-α, upregulation of vascular endothelial growth factor (VEGF), TGF-β, and fibronectin. NPWT, has been utilized for the past 20 years to treat various non-healing ulcers, including pressure sores. The gene discussed is TGFB1; the disease is decubitus ulcer.